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ABSTRACT
This study aims to evaluate the feasibility of a magnetic resonance (MR) automatic 
method for quantitative assessment of the percentage of fibrosis developed within 
locally advanced rectal cancers (LARC) after neoadjuvant radiochemotherapy (RCT). 
A total of 65 patients were enrolled in the study and MR studies were performed 
on 3.0 Tesla scanner; patients were followed-up for 30 months. The percentage of 
fibrosis was quantified on T2-weighted images, using automatic K-Means clustering 
algorithm. According to the percentage of fibrosis, an optimal cut-off point for 
separating patients into favorable and unfavorable pathologic response groups 
was identified by ROC analysis and tumor regression grade (MR-TRG) classes were 
determined and compared to histopathologic TRG. An optimal cut-off point of 81% of 
fibrosis was identified to differentiate between favorable and unfavorable pathologic 
response groups resulting in a sensitivity of 78.26% and a specificity of 97.62% for 
the identification of complete responders (CRs). Interobserver agreement was good 
(0.85). The agreement between P-TRG and MR-TRG was excellent (0.923). Significant 
differences in terms of overall survival (OS) and disease free survival (DFS) were 
found between favorable and unfavorable pathologic response groups. The automatic 
quantification of fibrosis determined by MR is feasible and reproducible.
INTRODUCTION
Magnetic Resonance (MR) is the most accurate 
imaging modality to stage locally advanced rectal cancer 
(LARC). MR role in stratification of patient risk and in 
guiding patient management has been widely investigated 
[1–6]. The strength of this technique is based on its 
ability to distinguish normal rectal wall from pathologic 
tissues on the basis of the differences in signal intensity 
achievable on T2-weighted sequences [4].
Neoadjuvant radiochemotherapy (RCT), which is 
the treatment of choice in patients with locally advanced 
rectal cancer (LARC) [7, 8], induces a development of 
fibrosis within the tumor which decreases the contrast with 
vital tissue. Thus, the use of MR for restaging after RCT 
is hampered by the difficulty to distinguish post-treatment 
fibrosis from residual tumor, due to their very similar T2 
signal intensity [9].
Identification of complete responders (CR) after 
RCT is crucial because there is an accumulating evidence 
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that in these patients, surgery may be deferred and an 
active surveillance can be performed [10, 11]. There is no 
consensus on the method to identify CR after RCT [12].
Histopathological tumor regression grade (P-TRG), 
defined as the ratio between fibrosis and residual tumor, 
is routinely used to assess response to therapy and 
demonstrated to be an important predictor of patient’s 
outcome [13–16].
Previous experiences [17–19] developed a TRG 
system based on MR T2 weighted sequences by applying 
the principles of histopathological grading, MR-TRG, and 
demonstrated a good correlation with patient’s outcome. 
However, in all published experiences, the quantification 
of fibrosis was assessed on the basis of a visual evaluation 
performed by experienced radiologists, reporting variable 
results [17–19].
The primary aim of our study was to develop an 
algorithm for automatic quantification of the fibrosis 
induced by RCT and to evaluate whether it can be used to 
identify CRs. The secondary aim of the study was to use 
the quantitative evaluation of fibrosis to develop an MR-
TRG score and to evaluate the agreement with P-TRG.
RESULTS
A total of 65 patients completed all the three phases 
of the study (Figure 1). Twenty-three patients (35.3%) 
achieved complete response (pCR) at histology, while 42 
patients (64.7%) achieved either partial response (pPR) or 
no response (pNR). No differences in terms of sex, age or 
tumor characteristics were observed between pCR and pP/
NR. Patients characteristics are summarized in Table 1.
Figure 1: Study population. Flow chart detailing the patient selection process.
Oncotarget114748www.impactjournals.com/oncotarget
MR acquisitions were performed between 38 and 48 
days (mean: 45.66, median: 43.44, SD: ±1.58) after the 
end of neoadjuvant RCT and between 4 and 7 days (mean: 
5.02, median: 4.95, SD±0.76) before surgery.
Mean time consumed for contouring the entire 
tumor volume was 10 minutes (± 3.62 minutes, median: 
9.5 minutes).
According to ROC analysis, a cut-off value of 81% 
of fibrosis was identified to discriminate between favorable 
and unfavorable pathologic response groups. Thus, in the 
group of favorable pathologic response were included only 
tumors with a percentage of fibrosis equal or greater than 
81%. Accordingly, in the group of unfavorable pathologic 
response all tumors with a percentage of fibrosis equal or 
lower than 80% were included.
Performances of the automatic quantification of 
fibrosis algorithm are summarized in Table 2. Using the 
aforementioned cut-off value of fibrosis, a sensitivity of 
78.26% (95% CI: 56.3 – 92.5) and specificity of 97.62% 
(95% CI: 87.4 – 99.9) were calculated (Figure 2). Eighteen 
of the 23 pCRs (78%) were included in the favorable 
group. Five pCRs (22%) were included in the unfavorable 
groups. One pP/NR (2%) was included in the favorable 
group.
According to ROC analysis a lower cut-off value of 
62% of fibrosis corresponds to a sensitivity of 100% (95% 
CI: 85.2 – 100) and a specificity of 54.76% (95% CI: 38.7 
– 70.2) while a higher cut-off value of 83% of fibrosis 
corresponds to a sensitivity of 73.9% (95% CI: 51.6 – 
89.8) and a specificity of 100% (95% CI: 91.6 – 100).
During the follow-up period (30 months), 14 
patients (21.5%) died as a result of cancer-related causes. 
Twenty-five (38%) patients had disease progression for 
local recurrences with or without metastatic disease.
A significant difference between favorable and 
unfavorable pathologic response groups for OS and DFS 
Table 1: Baseline characteristics of patient’s population
Characteristics Total pCR pNR/pPR P-value
Sex 0.65
 Male 44(66.7%) 14 (60.9%) 29 (69.1%)
 Female 21 (33.3%) 9 (39.1%) 13 (30.9%)
Age y (±SD) 64.8 (±8.43) 62.5 (±6.7) 65.3 (±9.2)
T stage 0.78
 2 1 (1.5%) 1 (4.3%) 1 (2.3%)
 3 56 (86.2%) 19 (82.6%) 36 (85.7%)
 4 8 (12.3%) 3 (13.1%) 5 (12%)
N stage 0.15
 0 12 (18.4%) 5 (21.7%) 8 (19.1%)
 1 26 (40%) 6 (26.1%) 18 (42.8%)
 2 27 (41.6%) 12 (52.2%) 16 (38.1%)
Overall stage 0.26
 II 12 (18.4%) 5 (21.7%) 8 (19.1%)
 IIIA 1 (1.5%) 0 (0%) 1 (2.3%)
 IIIB 27 (41.6%) 7 (30.4%) 19 (45.3%)
 IIIC 25 (38.5%) 11 (47.9%) 14 (33.3%)
Tumor dimension 0.23
 ≤ 5 cm 43 (66.2%) 18 (78.3%) 26 (61.9%)
 > 5 cm 22 (33.8%) 5 (21.7%) 16 (38.1%)
Distance from anal verge 0.32
 ≤ 5 cm 37 (56.9%) 14 (60.9%) 23 (54.7%)
 >5 ≤ 8 cm 15 (23.1%) 2 (8.7%) 11 (26.2%)
 > 8 cm 13 (20%) 7 (30.4%) 8 (19.1%)
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Table 2: Accuracy for the detection of CRs
95% CI P value
AUC 0.947 0.861 to 0.987 <0.0001
sensitivity 78.26 56.3 – 92.5
specificity 97.62 87.4 – 99.9
PPV* 94.7 74.0 – 99.9
NPV** 89.1 76.2 – 96.4
* Positive predictive value; ** negative predictive value.
Figure 2: ROC curves. The figure shows the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) Curve 
Analysis with 95% Confidence Limits (AUC = 0.947 and CI: 0.861 - 0.987).
was observed; hazard ratios were 5.31 (95% CI, 1.81 
to 15.55) and 4.20 (95% CI, 1.88 to 9.39) respectively. 
Kaplan-Meier survival curves are shown in Figure 3.
Median OS time at 30 months for patients with 
unfavorable pathologic response was 27.58 months (95% 
CI, 25.83 to 29.34) compared with 30 months (95% CI, 
30 to 30) for patients with favorable pathologic response 
(P=0.0023).
Median DFS at 30 months for patients with 
unfavorable pathologic response was 22.16 months (95% 
CI, 19.47 to 24.85) compared with 29.08 months (95% 
CI, 27.87 to 30.29) for patients with favorable pathologic 
response (P=0.0005).
The interobserver agreement for the manual 
contouring and quantification of the tumor volume was 
moderate (ICC=0.48; 95% CI, 0.26 to 0.76; P=0.0216) 
while the one for the automatic quantification of the 
percentage of fibrosis was very good (ICC=0.89; 95% CI, 
0.83 to 0.93; P<0.0001).
The agreement between MR-TRG and P-TRG 
classes was very good (weighted kappa = 0.91; 95% CI = 
0.85 – 0.94; P<0.0001).
DISCUSSION
Our results demonstrated that the automatic fibrosis 
quantification is feasible and reproducible. The proposed 
method provided high sensitivity and specificity for 
the identification of CR after neoadjuvant RCT. The 
automatic fibrosis quantification was able to identify 
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CR and P/NR, with high sensitivity (78%), specificity 
(97%) and AUC (0.947). These results should be 
compared to previous studies using a visual assessment 
and histology as reference standard. Bhoday et al [19] 
correctly identified 17 out of 18 CRs in a total population 
of 143 patients using a cut-off value of 50% of fibrosis 
to classify favorable MR-TRG group. However, using 
this cut-off value a large number of false positives were 
observed resulting in an overall sensitivity of 15.3% and a 
specificity of 96.9%. Patel et al [6], using the same visual 
approach of Bhoday et al, reported a sensitivity of 61.7% 
and a specificity of 90.9% for identification of ypT0-T3a 
tumors considered as favorable result after neoadjuvant 
RCT. Performances of our software-based method are 
notable not only in terms of sensitivity and specificity, but 
especially because in our cohort only pT0 tumors were 
considered as CRs.
Other MRI biomarkers have been proposed for 
identification of CRs. In particular, diffusion weighted 
imaging (DWI) and dynamic contrast-enhanced MRI 
(DCE-MRI) showed the highest accuracy. A recent study 
reported a sensitivity of 35% and a specificity of 94% [25] 
combining DWI and T2w morphologic sequences. It has 
been demonstrated that the evaluation of DWI volumes 
increases the sensitivity of this biomarker up to 64% [26]. 
Several studies investigated the accuracy of DCE-MRI 
reporting variable results. However, the evaluation of 
standardized index of shape (SIS), demonstrated to be the 
most accurate and reproducible method to identify CRs 
with a sensitivity higher than 90% and a specificity higher 
than 80% [27, 28].
In the era of organ preservation strategies, it 
is crucial to correctly identify CRs, needing a high 
sensitivity, but it is even more important to correctly 
classify P/NR, needing a high specificity, to avoid the 
delay of surgery in a patient with residual tumor.
Because the automatic fibrosis quantification can be 
used to determine MR-TRG classes, a comparison with 
P-TRG should be performed. We found a good correlation 
between the two methods (weighted kappa: 0.91), as 
opposite to a previously published study [29]. One of the 
possible explanation of the good results obtained is the 
use of 3.0 Tesla MRI scanner while most of the previous 
literature is based on datasets acquired on 1.5 Tesla 
systems. The higher strength of the magnetic field is, in 
fact, associated with a higher signal and overall higher 
image quality.
Despite our good results, a limitation of our 
approach should be underlined. The algorithm we used 
divides pixels necessarily into two groups: high signal 
for residual tumor and low signal for fibrosis. With this 
approach, MR-TRG 0 and 5 (respectively 100% and 
0% of fibrosis) cannot be calculated, thus we grouped 
p-TRG 0 and 1 as well as p-TRG 4 and 5 and we finally 
compared four TRG classes for both p-TRG and MR-
TRG. However, a real site-to-site comparison between the 
two methods is difficult to be realized in clinical practice, 
since it would require the surgical specimen to maintain 
the in vivo anatomy (as in MRI) while it is preliminarily 
dissected and fixed in formalin. Another major difference 
is that the evaluation with MRI is performed on the entire 
tumor volume while histopathology is performed on 
sample sections.
Histopathologic TRG has been shown to be an 
independent prognostic factor after neoadjuvant RCT 
[30, 31]. And studies using MR-TRG demonstrated 
similar data, showing a significant difference in terms 
of OS and DFS between poor and good MR-TRG 
groups [6, 32, 33]. Also, our results found a significant 
difference in terms of OS and DFS between favorable and 
unfavorable pathologic response groups determined with 
our algorithm.
One of the main limits of the visual fibrosis 
quantification is the poor interobserver agreement. 
The reproducibility of the method has been previously 
investigated reporting a variable agreement between 
readers, ranging between poor and good [18, 29, 34]. 
In these previous publications, a higher agreement was 
Figure 3: Kaplan Meier curves. Kaplan-Meier curves of DFS (a) and OS (b) for unfavorable and favorable group.
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Table 3: Exclusion criteria
Evidence of contraindications to MR examination (e.g. pacemaker, cochlear implant, etc.).
Incomplete MR acquisition or histopathological analysis.
Contraindication to the use of neoadjuvant therapy or surgical treatment.
Suspension of neoadjuvant combination chemotherapy-radiation treatment prior to surgery, presence of synchronous 
tumors, mucinous histotype, neurological or psychiatric disorders or previous pelvic radiotherapy.
Hypersensitivity to the study drug or to one of the excipients.
Legal incapacity.
Concurrent treatment with experimental drugs or participation in another clinical trial with any investigational drug within 
30 days before study screening.
Alcohol or drug abuse.
Table 4: MR protocol
Sequence Planes TR/TE (msec) NEX Matrix
Slice 
thickness 
(mm)
Other
2D FRFSE* T2w
orthogonal and 
parallel to the 
long axis of the 
tumor
4172 / 
122.3
2 512x512 4
2D SSEPI** DWI Axial 4400 / 
81.4
256x256 4
B values: 0, 10, 20, 30, 50, 60, 100, 
200, 600, 800 and 1000 sec/mm2
3D FSPGR*** T1w Axial 13.6 / 3.3 2 512x512 4 FA: 15°
3D FSPGR*** T1w
(perfusion imaging)
Axial
13.6 / 
3.3 2 512x512 4
IV administration of 2ml/kg of body 
weight of gadolinium chelate followed 
by a 15 ml saline flush at a rate of 
2 ml/s.
* Fast Relaxation Fast Spin Echo; ** Single-Shot Echo Planar Imaging; *** Fast Spoiled Gradient-Echo.
Figure 4: Quantification of fibrosis percentage. This example shows the native T2w images and the corresponding one elaborated 
with our software. The gray pixels represent the low signal intensity (fibrosis) and the white ones the high signal intensity (residual tumor). 
The histogram shows the distribution of pixels on the basis of their signal intensity.
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observed for identification of poor responders compared 
with good responders. Moreover, Patel et al [18] found 
disagreement between central reviewer and second 
reviewer (expert reader and less experienced reader, 
respectively) in the identification of complete responders, 
due to a higher percentage of good responders assessed 
by the central reviewer, this result demonstrated the 
influence of experience in visual assessment. In our 
study, to reduce potential bias related to reader expertise, 
we used low experienced readers (fifth year residents 
in radiology), and we found a moderate interobserver 
agreement (ICC: 0.48) for the manual quantification of 
the tumor volume which is an operator dependent process. 
However, the interobserver agreement for the automatic 
fibrosis percentage quantification, based on the datasets 
manually contoured by the operators, returned very good 
(ICC=0.89). This result underlines the usefulness of an 
automatic quantification method, which is crucial to 
standardize the procedure.
The time consumed to draw the ROI around the 
margins of the tumor on all axial slices, consisting in 10 
minutes per dataset, should be considered as a limit of 
the proposed method. However, despite this drawback, 
the computing system we used only takes few seconds to 
perform the analysis.
Despite the excellent performances of the proposed 
method, we should underline some limitations. First, 
the quantification of the percentage of fibrosis was a 
retrospective process performed on a prospectively 
recruited population. Second, the study population is 
relatively small. Nevertheless, our sample size is similar 
to the ones reported in most of the previous studies. Third, 
we did not validate the method on a control group. Finally, 
we applied our approach only to T2 weighted images. 
Theoretically, the algorithm we used also works with 
other sequences like DWI or perfusion maps. However, 
this would require a dedicated study.
In conclusion, our results demonstrated that 
automatic fibrosis quantification with MRI is feasible, 
provides better results compared to visual assessment and 
can be considered a reliable method to identify CRs after 
neoadjuvant RCT.
MATERIALS AND METHODS
Subjects
The study was conducted according to Good 
Clinical Practice (GCP)-International Conference on 
Harmonization (ICH) [20]. All patients signed a written 
informed consent to be enrolled in the study. The protocol 
was approved by the Local Ethical Committee (Rif. 
2737/28.03.2013).
All patients were enrolled between May 2013 and 
December 2014.
Patients with histologically-confirmed rectal 
adenocarcinoma (Stage II and Stage III according to the 
International Union Against Cancer (IUCC) classification 
[21]), were included in this non-randomized, prospective, 
multi-center trial (two centers). Exclusion criteria are 
listed in Table 3.
All patients underwent optical colonoscopy with 
biopsy for immunohistochemical analysis and an MR 
study for tumor staging. Two weeks after staging, patients 
started the neoadjuvant RCT protocol. An MR study for 
restaging after RCT was performed within one week 
before surgery. All patients underwent total mesorectal 
excision (TME) 6-8 weeks after the end of RCT. All 
gross specimens were analyzed by one single pathologist. 
Patients were followed up for thirty months at intervals 
of three months with physical examination, routine blood 
tests and yearly whole body computed tomography to 
assess local recurrences or distant metastases.
MR protocol and image analysis
All MR examinations were performed using 
a 3T scanner (Discovery MR750, General Electrics, 
Milwaukee, Wisconsin, USA) using a phased-array coil, 
with the protocol described in Table 4.
For the purpose of this study, only T2 weighted 
images acquired after neoadjuvant RCT were analyzed.
Following a previous experience [22], we 
decided to use the algorithm K-means for the automatic 
quantification of fibrosis. This algorithm, implemented 
in an in-house software developed in MATLAB software 
(The MathWorks Inc., Natick, Massachusetts, United 
States), automatically partitions data (n) into k numbers 
of mutually exclusive clusters; (k<n). The number of 
partitions is driven by the operator. We set k = 2 to cluster 
pixels into two partitions on the basis of their median 
signal intensity: a high signal intensity partition assumed 
to represent the residual tumor and a low signal intensity 
partition assumed to represent fibrosis (Figure 4).
Before the automatic analysis, a manual contouring 
of the entire tumor volume was performed on each axial 
section of T2-weighted images.
Tumor volume was considered as the entire mass 
appreciable including both fibrosis and vital tissue and 
excluding the lumen of the colon.
Two fifth year residents in radiology (with 1-year 
of experience on MR of the rectum), separately, manually 
contoured each lesion with 3D-slicer, a free platform for 
biomedical research (Brigham and Women’s Hospital, 
Boston, MA, USA). Time consumed to contour the entire 
tumor volume was recorded.
The manual contouring process provided as output 
the total tumor volume in cubic millimeters. The contoured 
dataset was processed with the k-means algorithm which 
provided two outputs, the volumes of low (fibrosis) and 
Oncotarget114753www.impactjournals.com/oncotarget
high (residual tumor) signal intensity pixels in cubic 
millimeters.
The percentage of fibrosis within the total tumor 
volume was calculated according to the following formula:
(Fibrosis volume / Tumor volume) x 100
Then, we divided tumors into four classes, according 
to the P-TRG described by Dworak-Rodel, on the basis of 
the percentage of fibrosis developed after RCT. Thus, in 
MR-TRG class 1 were grouped all tumors with ≤ 25% 
of fibrosis, in class 2 between 26% and 50%, in class 3 
between 51% and 75% and in class 4 ≥ 76%.
P-TRG Assessment
A pathologist, blinded to MR and biopsy findings, 
analyzed in random order all the gross specimens. The 
rectal segment harboring the neoplasm was examined 
by sectioning orthogonal to the long axis, obtaining 
2-3 mm thick macro section specimens. According to 
Dowrak-Rodel technique tumor regression was semi-
quantitatively assessed by the amount of viable tissue 
versus the amount of fibrosis, ranging from no evidence 
of fibrosis to a complete response with no residual tumor 
identifiable, [23].
Neoadjuvant radiochemotherapy
Radiochemotherapy was administered following the 
standard of care in our hospital [24]. Radiation therapy 
was performed with a fractioned 3D-conformational 
technique (45 Gy in 5 weeks) to the whole pelvis. An 
additional dose of 5.4-9 Gy was administered to the tumor 
volume in 3-5 days (6-15 MV energy photons).
Chemotherapy was administered through a central 
venous access (port-a-cath) as follows: 5 or 6 cycles of 
oxaliplatin (2-hour infusion 50 mg/m2) the first day of each 
week of radiotherapy followed by five daily continuous 
infusions of 5-FU 200 mg/m2/die.
Oxaliplatin infusion was preceded by desamethasone 
(8 mg) and ondansetron (8 mg) administration. Toxicity 
was evaluated according to NCI-CTC version 3.0dsds.
Statistical analysis
All continues variables were expressed as median 
and mean ± standard deviation (SD).
The percentage of fibrosis developed after RCT 
was automatically determined by the K-means algorithm. 
An optimal cut-off value of percentage of fibrosis for 
separating patients into favorable and unfavorable 
pathologic response groups was identified by receiver 
operating characteristics (ROC) analysis, with Youden 
index. This was done plotting the percentage of fibrosis as 
absolute value and the result of histology, dichotomized as 
complete responder (CR) or partial/non-responder (P/NR).
Diagnostic performance for the identification of 
CR was calculated by means of ROC curves. The area 
under the curve (AUC), sensitivity (SE), specificity (SP), 
positive predictive value (PPV) and negative predictive 
value (NPV) were calculated.
Differences in terms of overall survival (OS) and 
disease free survival (DFS) between favorable and 
unfavorable pathologic response groups were calculated 
by using Kaplan-Meier product limit method with 
univariate log-rank test.
Since the process includes two steps, consisting 
of manual contouring of the tumor and the automatic 
quantification of the percentage of fibrosis, the 
reproducibility was evaluated for each step by means of 
intraclass correlation coefficient (ICC).
Weighted Kappa statistic was performed to evaluate 
the agreement between MR-TRG and P-TRG classes.
Statistical analyses were carried out using a 
commercially available statistical software (MedCalc 
Statistical Software version 16.4.3, MedCalc Software 
bvba, Ostend, Belgium and GraphPad Prism version 5.0, 
GraphPad Software, La Jolla, California, USA). A two-
tailed P < 0.05 was considered statistically significant.
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